Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,619 across all filing types
Latest filing 2020-08-07 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
关于提请股东大会非关联股东批准深圳海王集团股份有限公司免于以要约方式增持股份的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Shenzhen Haiwang Bioengineering Co., Ltd. regarding a proposal to the shareholders' meeting to approve the exemption of the controlling shareholder, Shenzhen Haiwang Group Co., Ltd., from making a mandatory tender offer when increasing its shareholding through a non-public issuance of shares. The text discusses the number of shares to be issued, the price, the controlling shareholder's current and post-issuance shareholding percentage, and references the relevant regulatory provisions about tender offer exemptions. The document is an announcement related to capital raising and share issuance activities, specifically a non-public share issuance and related shareholder approval matters. It is not a full financial report, audit, or earnings release, nor is it a voting result or management change announcement. The content fits best under Capital/Financing Update (CAP) as it details the company's financing activity and capital structure changes through a non-public share issuance and related shareholder approval.
2020-08-07 Chinese
关于与深圳海王集团股份有限公司签署附条件生效的《深圳市海王生物工程股份有限公司非公开发行A股股票之股份认购合同》的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the signing of a conditional subscription agreement for a non-public issuance of A shares by Shenzhen Haiwang Bioengineering Co., Ltd. It details the contract parties, subscription amount, pricing, payment method, conditions for contract effectiveness, and breach liabilities. The content focuses on a capital raising transaction through a private placement of shares, including subscription terms and regulatory approvals required. There are no financial statements or quarterly/yearly performance data, nor is it a report or presentation. The document is a formal announcement of a capital/financing update related to share issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is 2440 characters, consistent with an announcement rather than a full report.
2020-08-07 Chinese
关于终止公司2019年非公开发行股票事项并撤回申请文件的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the termination of its 2019 non-public issuance of A-shares and the withdrawal of the application to the China Securities Regulatory Commission. It details the decision-making process, reasons for termination, and the impact on the company. The content focuses on capital raising activities and the cessation of a financing plan rather than presenting financial statements or detailed financial results. The document length is short (1350 characters), and it is clearly an announcement about a capital/financing update rather than a full report or regulatory filing. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2020-08-07 Chinese
关于召开2020年第三次临时股东大会通知的公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed announcement regarding the convening of the 2020 third extraordinary general meeting of shareholders of Shenzhen Haiwang Bioengineering Co., Ltd. It includes information about the meeting time, location, agenda items (mainly about a non-public stock issuance plan), voting procedures, and proxy authorization. The content focuses on notifying shareholders about the meeting and the proposals to be voted on, rather than presenting financial results or detailed financial statements. The document is not a report itself but an official notice for a shareholders' meeting with agenda details and voting instructions. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2020-08-07 Chinese
独立董事关于第八届董事局第十一次会议相关事项的专项说明和独立意见
Board/Management Information Classification · 90% confidence The document is a special statement and independent opinion from independent directors regarding the company's external guarantees and fund occupation for the half-year period ending June 30, 2020. It references regulatory guidelines and compliance with relevant laws. The content is focused on governance and compliance matters related to the half-year financial period but does not contain actual financial statements or detailed financial data. The document length is short (920 characters), and it is a formal opinion rather than a full interim or annual report. Therefore, it fits best under Board/Management Information (MANG) as it relates to board-level opinions and governance matters rather than a full financial report or audit.
2020-08-03 Chinese
2020年半年度报告
Interim / Quarterly Report Classification · 98% confidence The document is titled "深圳市海王生物工程股份有限公司 2020 年半年度报告全文" which translates to "Shenzhen Neptunus Bioengineering Co., Ltd. 2020 Semi-Annual Report Full Text." It covers the period from January 1, 2020 to June 30, 2020, indicating it is a report for a period shorter than a full fiscal year. The content includes detailed financial data such as revenue, net profit, cash flow, segment analysis, business overview, management discussion and analysis, and other comprehensive financial and operational information. The length of the document is about 15,000 characters, which is substantial and contains actual financial statements and analysis. This matches the definition of an Interim / Quarterly Report (IR). It is not an announcement or a brief summary, nor is it a full annual report (10-K). Therefore, the correct classification is IR with high confidence. H1 2020
2020-08-03 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.